Expand your arsenal of patient-reported outcomes (PRO) tools and find out how they can impact your practice. Explore the options with this webcast from our symposium at the European Oncology Congress in Madrid. Experts provide an in-depth examination of supportive care in oncology focused on how to provide the best possible care for patients by incorporating patient-reported outcomes into your standard of care.
1.5 AMA PRA Category 1 Credits™
Oct 17, 2017
Oct 17, 2018
Overview on the impact of treatment on patient well-being in oncology
Florian Strasser, MD
Focus on economics in supportive care: Comparing treatment costs to the cost of not treating
Alexander Molassiotis, RN, PhD
Overview on current and emerging tools for identifying and capturing PROs in cancer care
Stein Kaasa, MD, PhD
These tools really work: Current data on the impact of using PROs in assessing patient symptoms/quality of life and potential barriers that may prevent their implementation
Stein Kaasa, MD, PhD
Current and emerging treatment options for commonly-reported symptoms/issues in oncology
Richard Gralla, MD, FACP
Florian Strasser, MD
Florian Strasser, MDCantonal Hospital St Gallen
St Gallen, Switzerland
Richard Gralla, MD, FACPAlbert Einstein College of Medicine
New York, New York, United States
Stein Kaasa, MD, PhDOslo University Hospital and Oslo University
Alexander Molassiotis, RN, PhDThe Hong Kong Polytechnic University
Hong Kong, China
This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, surgical oncologists, radiation oncologists, hematology/oncology nurses, and other healthcare professionals involved in providing supportive care to patients with cancer.
After successful completion of this educational activity, participants should be able to:
- Assess the impact that cancer treatment can have on patient quality of life, general well-being, and overall functioning
- Identify current and emerging tools that can aid in the assessment of PROs in oncology
- Interpret data on the impact of using PROs on patient quality of life, general well-being, and overall functioning in the oncology setting
- Develop optimal supportive care strategies for patients with cancer who experience issues such as chemotherapy-induced nausea and vomiting, chemotherapy-induced diarrhea, and cancer cachexia
- Analyze efficacy and safety data on emerging treatment strategies in supportive care
This educational activity is supported by a grant from Helsinn Healthcare SA.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Gralla has disclosed that he has received compensation for speaking and teaching engagements from Chugai, Galenica, Helsinn Healthcare SA, and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Kaasa has disclosed that he has ownership interest in Eir Solutions. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Molassiotis has disclosed that he has received consulting fees from Helsinn Healthcare SA, Merck & Co Ltd, and Tesaro. He has performed contracted research/received support from Acacia Pharma. Dr Molassiotis has also received fees for non-CME services directly from commercial interest or their agents from Helsinn Healthcare SA and Merck & Co Ltd. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Strasser has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
• Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
• Briana Betz, PhD (Scientific content reviewer/planner) – no relevant financial relationships
• Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.